Menu
Recruiting NCT06601699

Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 2

No phase Interventional Healthy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Transcranial electrical stimulation (TES), Transcranial electrical stimulation with temporal interference (TES-TI).
Who it may be relevant to
Registry conditions: Healthy. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study

Overview

The goal of this clinical trial is to learn whether brain stimulation technology can help people reach a meditative state quickly and easily without years of meditation training. The researchers want to see if this will help people distance themselves from their thoughts and feeling, and if this will lead to improvements in openness and wellbeing the same way meditation can. Participants will: * Complete questionnaires * Perform a guided meditation task (The Bell Task) * Wear a high density electrocochleography (hdEEG) cap * Undergo brain stimulation

Detailed description

This study is being done to evaluate the relative effectiveness of distinct types of non-invasive brain stimulation - NIBS (TES-TI and TES) on subjective ego disengagement and cortical activity in experienced meditators and meditation naïve healthy adults.

Stage 1a was designed to establish the optimal level of stimulation to achieve ego displacement in experienced meditators. Stage 1b used the level of stimulation established in 1a to discern the region of the posteromedial cortex (PMC) where disruption is most effective in achieving ego displacement in experienced meditators. This stage, stage 2 will use the most effective stimulation and PMC parameters to meditation naïve healthy adults.

Primary Objective (stage 2):

\- To evaluate the effectiveness of NIBS on ego disengagement and cortical activity in meditation naïve healthy adults acutely and longitudinally

Secondary Objectives (stage 2):

* Evaluate the relationships between NIBS, ego-disengagement, and trait assessments openness and wellbeing * Evaluate the effect of the use of topical anesthetics on the EEG response evoked by NIBS

Interventions

  • Device Transcranial electrical stimulation (TES)
    TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
  • Device Transcranial electrical stimulation with temporal interference (TES-TI)
    TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.

Primary outcome measures

  • Ego-Disengagement scale [Time frame: baseline, week 1, week 2, week 3, week 7]
  • Cortical activity - change in gamma band power [Time frame: week 1, week 2, week 3, final visit (week 7)]
  • Cortical activity - change in alpha band power [Time frame: week 1, week 2, week 3, final visit (week 7)]
Secondary outcome measures (8)
  • Change in Big Five Aspects Scale (BFAS) [Time frame: baseline to week 7]
  • Change in Fulfilled Life Scale (FLS) [Time frame: baseline to week 7]
  • Change in PROMIS Anxiety [Time frame: baseline to week 7]
  • Change in PROMIS Depression [Time frame: baseline to week 7]
  • Change in Perceived Stress Scale (PSS) [Time frame: baseline to week 7]
  • Change in Questionnaire for Eudaimonic Well-Being (QEWB) [Time frame: baseline to week 7]
  • Cortical activity - change in alpha band power (topical anesthetic vs. no topical anesthetic) [Time frame: week 1, week 2, week 3, final visit (week 7)]
  • Cortical activity - change in gamma band power (topical anesthetic vs. no topical anesthetic) [Time frame: week 1, week 2, week 3, final visit (week 7)]

Eligibility criteria

Inclusion criteria

  • Adults, ages 18 to 80 of any identified gender
  • Medically healthy
  • English-speaking (able to provide consent and complete questionnaires)
  • Healthy adults who are meditation-naïve
  • Citizen or legal resident

Exclusion criteria

  • Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions
  • Any current or past history of bipolar disorder and/or hypomania
  • Any current or past history of psychosis
  • History of head trauma resulting in prolonged loss of consciousness; or a history of great than 3 grade I concussions
  • Current history of poorly controlled headaches including intractable or poorly controlled migraines
  • Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures
  • History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
  • Possible pregnancy. All female participants of child-bearing age are required to have a pregnancy test
  • Any metal in the brain, skull or head
  • Any contraindications to MRI
  • Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator, dental implants (this includes a permanent retainer)) unless otherwise approved by the responsible MD
  • Substance abuse or dependence within the past six months
  • Any medication that may alter seizure threshold i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic/atypical antidepressants (Amitriptyline, Dioxepine, Imipramine Maprotiline, Nortriptyline, Bupropion); Antipsychotics (Chlorpromazine, Clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antiviral (Valacyclovir, Ritonavir); OTC (Diphenhydramine)
  • Claustrophobia (a fear of small or closed places)
  • Back problems that would prevent lying flat for up to two hours
  • Having experienced a traumatic event that caused lasting distress or required treatment
  • Motion sickness
  • Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out or adjusted to permit comfortable and comprehensive participation before the MRI scans and/or stimulation sessions
  • Any head coverings or headdress that participant feels uncomfortable removing for the purposes of the MRI scans and/or stimulation session

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Single group
Masking
Single blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Wisconsin — Madison

Identifiers

NCT: NCT06601699 · 2023-0613 Stage 2 · A535100 · Protocol Version 4/10/2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗